



NORDIC NANOVECTOR

DLBCL next data point

Nordic Nanovector reported a slightly smaller Q3 operating loss than we forecast. The company raised new capital after the end of the quarter and should now have enough resources to take it to data read-out for the PARADIGME trial. It reiterated that the first data read-out from the LYMRIT 37-05 trial in DLBCL should be available before end-2019. We reiterate our BUY and NOK72 target price.

Q3 operating loss slightly smaller than we forecast. The company reported an operating loss of cNOK100m, compared to our estimate of a loss of cNOK105m. Of the operating spend in the quarter, c78% related to R&D activities. The cash position at the end of the quarter was cNOK346m, compared to our estimate of cNOK341m.

After the end of the quarter the company raised a gross cNOK234m. Adding this to the cash position, we believe the company should have enough resources to take it all the way to data read-out for the PARADIGME trial. At the presentation following the results, the company stated that it does not plan to update the market on the recruitment progress in the trial (beyond number of sites and countries). We believe that investor sentiment and confidence in the trial would benefit from the company providing more clarity about the progress of the PARADIGME trial.

Next data point – the initial read-out from the DLBCL trial. The company reiterated that the next data point will be the initial read-out from the DLBCL trial called LYMRIT 37-05 (expected before end-2019). Management was clear that the long-term goal in DLBCL is to use Betalutin as part of a combination therapy and not as a monotherapy. It would like to see some single agent activity in the LYMRIT 37-05 trial, but will most likely progress with a combination trial as the next step in our view.

BUY and NOK72 target price reiterated. We believe that the data seen from the development of Betalutin is strong with a very attractive combination of efficacy and side-effect profile.


Year-end Dec	2015	2016	2017	2018	2019e	2020e	2021e
Revenue (NOKm)	0	0	0	nm	nm	nm	nm
EBITDA adj (NOKm)	-182	-215	-315	-338	-398	-394	-360
EBIT adj (NOKm)	-183	-216	-317	-340	-408	-399	-367
PTP (NOKm)	-173	-235	-293	-337	-406	-398	-367
EPS rep (NOK)	-4.32	-5.05	-6.02	-6.88	-7.85	-7.32	-6.74
EPS adj (NOK)	-4.32	-5.05	-6.02	-6.88	-7.85	-7.32	-6.74
DPS (NOK)	0.00	0.00	0.00	0.00	0.00	0.00	0.00
Revenue growth (%)	-0.6	-28.1	-3.8	nm	nm	nm	nm
P/Book (x)	0.79	4.75	5.81	6.90	2.71	4.52	6.16
Dividend yield (%)	0.0	0.0	0.0	0.0	0.0	0.0	0.0

Source: Company (historical figures), DNB Markets (estimates)

BUY

TP: NOK72.0

NANO versus OSEBX (12m)



SUMMARY

Recommendation (prev.)	BUY (BUY)
Share price (NOK)	20.9
Target price (previous) (NOK)	72.0 (72.0)
Upside/downside potential (%)	245
Tickers	NANO NO, NANO.OL

CAPITAL STRUCTURE

No. of shares (m)	66.1
No. of shares fully dil. (m)	66.1
Market cap. (NOKm)	1,381
NIBD adj end-2019e (NOKm)	-481
Enterprise value adj (NOKm)	900
Net debt/EBITDA adj (x)	1.21
Free float (%)	47

Source: Company, DNB Markets (estimates)

Note: Unless otherwise stated, the share prices in this note are the last closing price.

NEXT EVENT

Q4 2019 report	27/02/2020
----------------	------------

ESTIMATE CHANGES (NOK)

Year-end Dec	2019e	2020e	2021e
Sales (old)	0.00	0.00	0.00
Sales (new)	0.00	0.00	0.00
Change (%)	nm	nm	nm
EPS (old)	-7.88	-7.32	-6.74
EPS (new)	-7.85	-7.32	-6.74
Change (%)	nm	nm	nm

Source: DNB Markets, Bloomberg

DNB Markets acted as Joint Global Coordinator in the recent private placement in Nordic Nanovector


ANALYSTS

Patrik Ling
patrik.ling@dnb.se
+46 8 473 48 43

Please see the last two pages for important information. This research report was not produced in the US. Analysts employed by non-US affiliates are not registered/qualified research analysts with FINRA in the United States.

Investment case overview

Share price performance, DNB Markets' target price, bear- and bull-case scenarios



Source: FactSet, DNB Markets

Downside risks to our investment case

- We still expect Betalutin to have a meaningful clinical effect. The biggest risk we see is that the development programme (which we believe is ambitious) might incur further delays.
- There is much focus on the NHL market from many big pharmaceutical companies; hence a potentially tougher competitive environment.
- Longer than expected approval times and changes to regulatory conditions.
- Lower realised prices than we have factored into our model.

Source: DNB Markets

DNB Markets investment case and how we differ from consensus

- In our base case, the company will develop Betalutin all the way to the market and launch the product alone.
- The first indication should reach the market in 2022. We have applied a 50% probability adjustment to FL sales, but development costs are unadjusted.
- We estimate a global average price per patient of USD150,000 for Betalutin for all indications.
- There is no meaningful consensus.

Source: DNB Markets

Target price methodology

- We continue to primarily base our target price on a SOTP, which includes the period until the patent expires, and is probability-adjusted. We discount the values back to a NPV with a WACC of 10%.
- Our bull-case fair value is based on our SOTP but with a higher peak penetration assumption than in our base case.
- Our bear-case fair value is based on our SOTP but with a lower peak penetration assumption than in our base case.


Source: DNB Markets

Upside risks to our investment case

- The company could become a target for consolidation in the industry.
- It might realise higher prices for Betalutin than we have factored in.
- With strong clinical data, the approval process might be speedier than we have estimated leading to a sooner than expected launch.

Source: DNB Markets

Operating costs bridge 2018–2020e (NOKm)



Source: DNB Markets (forecasts), company (historical data)

ESG overview

Sustainability assessment

	Positive	Negative
Conclusions	<ul style="list-style-type: none"> ■ Nordic Nanovector develops new drugs for the treatment of patients with different types of non-Hodgkin's Lymphoma (cancer). ■ There are large unmet medical needs in the areas the company focuses on. 	<ul style="list-style-type: none"> ■ Drug development is associated with high risk as significant investments are made into development projects that may never become finished products. ■ Developing new drugs is costly, time-consuming, and very risky.
Actions being taken by company	<ul style="list-style-type: none"> ■ The company does not have a partner for its main drug candidate and instead plans to take the drug all the way to the market on its own. ■ The company mainly addresses the UN sustainability goals number 3 (good health and well-being), but also 5, 8 and 9. 	<ul style="list-style-type: none"> ■ The company is engaged in animal studies and clinical trials in humans are performed.

Key ESG drivers

Short-term	<ul style="list-style-type: none"> ■ The healthcare industry is highly regulated and the safety of patients and test subjects always takes precedence over other concerns. ■ As the company does not have any products on the market yet, the environmental focus is today more geared towards the supply and manufacturing of products for clinical trials rather than for the market. 	<ul style="list-style-type: none"> ■ Treatment-related adverse events have occurred in clinical trials. ■ The clinical development programme has taken longer to execute than the company initially expected, but seems to have addressed the recruitment issues now.
Long-term	<ul style="list-style-type: none"> ■ The company has established CSR focus areas, where the safety and well-being of patients and employees comes first. The policies also focus on compliance for all stakeholders in the company. ■ Its lead drug candidate contains the radioactive material Lutetium-177, which generates beta-radiation, and is effective in treating NHL in a one-time treatment session with limited side-effects. 	<ul style="list-style-type: none"> ■ Nordic Nanovector is to a great extent dependent on key personnel. The ability to recruit and retain qualified personnel is of utmost importance to ensure the competence level in the company. ■ The handling of radioactive material must be controlled in order to avoid healthcare personnel being unintentionally exposed.

Source: DNB Markets

Sustainability assessment

	Risk	Company's risk mitigation
Transition risks		
Policy and legal	<ul style="list-style-type: none"> ■ Nordic Nanovector operates in a strictly regulated environment and must comply with laws and regulation governing drug development and manufacturing. 	<ul style="list-style-type: none"> ■ The company carefully monitors all laws and regulation to ensure that its work complies with current legislation.
Technology	<ul style="list-style-type: none"> ■ New targets for treating NHL might be developed and found more attractive than Nordic Nanovector's target. 	<ul style="list-style-type: none"> ■ The company actively monitors developments among competitors active in its field.
Market	<ul style="list-style-type: none"> ■ New drugs with better safety for the treatment of the diseases that Nordic Nanovector focuses on could reduce the need for its products. 	<ul style="list-style-type: none"> ■ The company has a pipeline of several drugs based on different antibodies and radioisotopes to broaden the potential use of its technologies.
Reputation	<ul style="list-style-type: none"> ■ The company wants to bring added value to Nordic Nanovector's stakeholders without compromising its integrity and reputation. 	<ul style="list-style-type: none"> ■ Transparency in stakeholder collaborations is key and is something the company is striving for.
Physical risk		
Acute	<ul style="list-style-type: none"> ■ Research and development of drugs is associated with high risk as great financial resources are invested in a project that may never become a finished medical product. Projects may be discontinued due to lack of efficacy or turn out to have too great negative side effects. 	<ul style="list-style-type: none"> ■ The project portfolio is an attractive combination of projects at different stages of development for different indications and some projects are run in partnership with other companies as well.
Chronic	<ul style="list-style-type: none"> ■ Emergence of new therapeutic approaches that pose significant competitive risk against Nordic Nanovector's drug candidates. 	<ul style="list-style-type: none"> ■ Mapping of relevant competitive landscape. Incorporation of scientific advisory and competitive intelligence resources.

Source: DNB Markets

Sustainability assessment

	Opportunities	Company's utilisation of opportunity
Resource efficiency	<ul style="list-style-type: none"> ■ The company contributes to sustainable development through research and development, and aims to reduce the environmental impact in its operations. 	<ul style="list-style-type: none"> ■ The company's objective is to contribute to sustainable development, and it works proactively to improve its environmental performance insofar as being economically feasible.
Products/Services	<ul style="list-style-type: none"> ■ As the company does not have any sales at this time, its products do not have an environmental impact in terms of GHG emissions. 	<ul style="list-style-type: none"> ■ Nordic Nanovector's areas of environmental impact pertain to the purchase of goods and services, energy consumption and transportation.
New markets	<ul style="list-style-type: none"> ■ The company is developing its drugs for several different indications and over time, potentially for completely new disease areas. 	<ul style="list-style-type: none"> ■ Nordic Nanovector has retained the core rights to all its drugs and is free to team up (if needed) with other companies.
Supply chain resilience	<ul style="list-style-type: none"> ■ Not relevant at this time, as the company does not have any products on the market yet. 	<ul style="list-style-type: none"> ■ Not relevant yet.

Source: DNB Markets

Forecast changes – P&L

(NOKm)	New			Old			Change		
	2019e	2020e	2021e	2019e	2020e	2021e	2019e	2020e	2021e
Revenues	0	0	0	0	0	0	0	0	0
Cost of sales	0	0	0			0			0
Gross profit	0	0	0	0	0	0	0	0	0
Operating expenses	-398	-394	-360	-403	-394	-360	5	0	0
EBITDA	-398	-394	-360	-403	-394	-360	5	0	0
EBITDA adj	-398	-394	-360	-403	-394	-360	5	0	0
EBITDA margin (%)	nm	nm	nm	high	high	high	nm	nm	nm
Depreciation	-10	-5	-7	-7		-7	-3		0
EBITA	-408	-399	-367	-410	-399	-367	2	0	0
EBIT	-408	-399	-367	-410	-399	-367	2	0	0
EBIT adj	-408	-399	-367	-410	-399	-367	2	0	0
Net interest	2	1	0			0			0
Net financial items	2	1	0			0			0
PBT	-406	-398	-367	-408	-398	-367	2	0	0
Taxes	0	0	0			0			0
Net profit	-406	-398	-367	-408	-398	-367	2	0	0
Adjustments to net profit	0	0	0	0	0	0	0	0	0
Net profit adj	-406	-398	-367	-408	-398	-367	2	0	0
<i>Per share data (NOK)</i>									
EPS	-7.85	-7.32	-6.74	-7.88	-7.32	-6.74	0.04	0.00	0.00
EPS adj	-7.85	-7.32	-6.74	-7.88	-7.32	-6.74	0.04	0.00	0.00
DPS ordinary	0.00	0.00	0.00			0.00			0.00
DPS extraordinary	0.00	0.00	0.00			0.00			0.00
DPS	0.00	0.00	0.00			0.00			0.00
<i>Other key metrics (%)</i>									
Revenue growth	nm	nm	nm	nm	nm	nm	nm	nm	nm
EBIT adj growth	nm	nm	nm	20.6	-2.7	-8.1	nm	nm	nm
EPS adj growth	nm	nm	nm	14.7	-7.2	-7.8	nm	nm	nm
Avg. number of shares (m)	54	57	57	54	57	57	0	0	0
Capex	-5	-5	-5	-5	-5	-5	0	0	0
OpFCF	-403	-399	-365	-408	-399	-365	5	0	0
Working capital	-78	-78	-78	-78	-78	-78	0	0	0
NIBD adj	-481	-333	-268	-476	-328	-263	-5	-5	-5

Source: DNB Markets

Quarterly numbers

(NOKm)	Q2 2018	Q3 2018	Q4 2018	Q1 2019	Q2 2019	Q3 2019	Q4 2019e	Q1 2020e	Q2 2020e	Q3 2020e	Q4 2020e
Revenues	0	0	0	0	0	0	0	0	0	0	0
Cost of sales	0	0	0	0	0	0	0	0	0	0	0
Gross profit	0	0	0	0	0	0	0	0	0	0	0
Operating expenses	-84	-76	-96	-89	-107	-97	-105	-98	-98	-98	-98
EBITDA	-84	-76	-96	-89	-107	-97	-105	-98	-98	-98	-98
Depreciation	-1	-1	-1	-1	-4	-4	-2	-1	-1	-1	-1
EBITA	-85	-77	-96	-90	-111	-100	-107	-100	-100	-100	-100
EBIT	-85	-77	-96	-90	-111	-100	-107	-100	-100	-100	-100
Net interest	2	2	8	-3	1	7	1	0	0	0	0
Net financial items	2	2	8	-3	1	7	1	0	0	0	0
PBT	-83	-75	-88	-93	-110	-94	-106	-99	-99	-99	-99
Taxes	0	0	0	0	0	0	0	0	0	0	0
Net profit	-83	-75	-88	-93	-110	-94	-106	-99	-99	-99	-99
Adjustments to net profit	0	0	0	0	0	0	0	0	0	0	0
Net profit adj	-83	-75	-88	-93	-110	-94	-106	-99	-99	-99	-99
<i>Per share data (NOK)</i>											
<i>Growth and margins (%)</i>											
Revenues, QOQ growth	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
Revenues, YOY growth	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
EPS adj, YOY growth	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
Gross margin	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
EBITDA adj margin	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
Depreciation/revenues	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
EBIT adj margin	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
Net profit margin	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm

Source: Company (historical figures), DNB Markets (estimates)

Adjustments to quarterly numbers

(NOKm)	Q2 2018	Q3 2018	Q4 2018	Q1 2019	Q2 2019	Q3 2019	Q4 2019e	Q1 2020e	Q2 2020e	Q3 2020e	Q4 2020e
EBITDA	-84	-76	-96	-89	-107	-97	-105	-98	-98	-98	-98
EBITDA adj	-84	-76	-96	-89	-107	-97	-105	-98	-98	-98	-98
EBITA	-85	-77	-96	-90	-111	-100	-107	-100	-100	-100	-100
EBITA adj	-85	-77	-96	-90	-111	-100	-107	-100	-100	-100	-100
EBIT	-85	-77	-96	-90	-111	-100	-107	-100	-100	-100	-100
EBIT adj	-85	-77	-96	-90	-111	-100	-107	-100	-100	-100	-100
Net profit	-83	-75	-88	-93	-110	-94	-106	-99	-99	-99	-99
Net profit adj	-83	-75	-88	-93	-110	-94	-106	-99	-99	-99	-99

Source: Company (historical figures), DNB Markets (estimates)

Annual P&L

(NOKm)	2012	2013	2014	2015	2016	2017	2018	2019e	2020e	2021e
Revenues	0	0	0	0	0	0	0	0	0	0
Cost of sales	0	0	0	0	0	0	0	0	0	0
Gross profit	0	0	0	0	0	0	0	0	0	0
Operating expenses	-13	-18	-69	-183	-216	-315	-338	-398	-394	-360
EBITDA	-13	-18	-68	-182	-215	-315	-338	-398	-394	-360
Depreciation	-1	0	0	-1	-1	-1	-2	-10	-5	-7
EBITA	-14	-18	-69	-183	-216	-317	-340	-408	-399	-367
EBIT	-14	-18	-69	-183	-216	-317	-340	-408	-399	-367
Net interest	0	1	5	10	-19	23	3	2	1	0
Net financial items	0	1	5	10	-19	23	3	2	1	0
PBT	-13	-17	-64	-173	-235	-293	-337	-406	-398	-367
Taxes	0	0	0	0	0	0	0	0	0	0
Effective tax rate (%)	0	0	0	0	0	0	0	0	0	0
Net profit	-13	-17	-64	-173	-235	-293	-337	-406	-398	-367
Adjustments to net profit	0	0	0	0	0	0	0	0	0	0
Net profit adj	-13	-17	-64	-173	-235	-293	-337	-406	-398	-367
Avg. number of shares	6	9	20	42	49	51	51	54	57	57
<i>Per share data (NOK)</i>										
EPS	-2.11	-1.92	-3.54	-4.32	-5.05	-6.02	-6.88	-7.85	-7.32	-6.74
EPS adj	-2.11	-1.92	-3.54	-4.32	-5.05	-6.02	-6.88	-7.85	-7.32	-6.74
DPS ordinary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
DPS extraordinary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
DPS	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
<i>Growth and margins (%)</i>										
Revenue growth	135.1	106.6	43.6	-0.6	-28.1	-3.8	nm	nm	nm	nm
EPS adj growth	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
Gross margin	100.0	100.0	100.0	100.0	100.0	100.0	nm	nm	nm	nm
EBITDA margin	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
EBITDA adj margin	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
Depreciation/revenues	-526.2	-77.4	-78.6	-227.5	-369.4	-491.1	nm	nm	nm	nm
EBIT margin	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
EBIT adj margin	-9278.3	-5917.5	nm	nm	nm	nm	nm	nm	nm	nm
PBT margin	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
Net profit margin	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm

Source: Company (historical figures), DNB Markets (estimates)

Adjustments to annual P&L

(NOKm)	2012	2013	2014	2015	2016	2017	2018	2019e	2020e	2021e
EBITDA	-13	-18	-68	-182	-215	-315	-338	-398	-394	-360
EBITDA adj	-13	-18	-68	-182	-215	-315	-338	-398	-394	-360
EBITA	-14	-18	-69	-183	-216	-317	-340	-408	-399	-367
EBITA adj	-14	-18	-69	-183	-216	-317	-340	-408	-399	-367
EBIT	-14	-18	-69	-183	-216	-317	-340	-408	-399	-367
EBIT adj	-14	-18	-69	-183	-216	-317	-340	-408	-399	-367
Net profit	-13	-17	-64	-173	-235	-293	-337	-406	-398	-367
Net profit adj	-13	-17	-64	-173	-235	-293	-337	-406	-398	-367
<i>Per share data (NOK)</i>										
EPS	-2.11	-1.92	-3.54	-4.32	-5.05	-6.02	-6.88	-7.85	-7.32	-6.74
Recommended adjustment	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
EPS adj	-2.11	-1.92	-3.54	-4.32	-5.05	-6.02	-6.88	-7.85	-7.32	-6.74

Source: Company (historical figures), DNB Markets (estimates)

Cash flow

(NOKm)	2012	2013	2014	2015	2016	2017	2018	2019e	2020e	2021e
Net profit	-13	-17	-64	-173	-235	-293	-337	-406	-398	-367
Change in net working capital	0	0	0	0	0	0	0	0	0	0
Cash flow from operations (CFO)	-13	-17	-63	-172	-234	-292	-335	-396	-393	-360
Capital expenditure	0	0	3	-2	-1	-3	-2	-5	-5	-5
Acquisitions/Investments	0	0	0	0	0	0	0	0	0	0
Cash flow from investing (CFI)	0	0	3	-2	-1	-3	-2	-5	-5	-5
Free cash flow (FCF)	-13	-17	-61	-174	-236	-294	-337	-401	-398	-365
Net change in debt	0	0	0	0	0	0	0	0	0	0
Other	2	3	5	34	45	65	12	0	0	0
Cash flow from financing (CFF)	2	90	318	580	510	33	20	442	250	300
Total cash flow (CFO+CFI+CFF)	-11	73	257	406	275	-262	-317	41	-148	-65
<i>FCFF calculation</i>										
Free cash flow	-13	-17	-61	-174	-236	-294	-337	-401	-398	-365
Less: net interest	0	-1	-5	-10	19	-23	-3	-2	-1	0
Less: acquisitions	0	0	0	0	0	0	0	0	0	0
Growth (%)										
CFO	-102.7	-32.4	-277.3	-171.3	-36.3	-24.8	-14.6	-18.3	0.8	8.4
CFI	108.7	-479.6	1031.8	-180.7	32.8	-67.8	14.1	-131.6	0.0	0.0
FCF	-76.1	-35.6	-254.5	-187.3	-35.4	-25.0	-14.4	-19.0	0.8	8.3
CFF	-84.0	4759.6	253.4	82.5	-12.0	-93.6	-37.9	2067.9	-43.4	20.0
FCFF	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm

Source: Company (historical figures), DNB Markets (estimates)

Balance sheet

(NOKm)	2012	2013	2014	2015	2016	2017	2018	2019e	2020e	2021e
Assets	11	86	346	760	1,045	780	474	509	362	295
Inventories	0	0	0	0	0	0	0	0	0	0
Trade receivables	4	6	7	14	23	20	29	29	29	29
Other receivables	0	0	0	0	0	0	0	0	0	0
Current financial assets	0	0	0	0	0	0	0	0	0	0
Cash and cash equivalents	7	80	337	743	1,018	757	440	481	333	268
Current assets	11	86	344	758	1,042	776	470	510	362	298
Property, plant and equipment	0	0	2	3	3	4	4	-1	-1	-3
Goodwill	0	0	0	0	0	0	0	0	0	0
Other intangible assets	0	0	0	0	0	0	0	0	0	0
Defferred tax assets	0	0	0	0	0	0	0	0	0	0
Non-current financial assets	0	0	0	0	0	0	0	0	0	0
Non-current assets	0	0	2	3	3	4	4	-1	-1	-3
Total assets	11	86	346	760	1,045	780	474	509	362	295
Equity and liabilities	11	86	346	760	1,045	780	474	509	362	295
Total equity to the parent	8	79	330	713	949	680	363	399	251	184
Total equity	8	79	330	713	949	680	363	399	251	184
Trade payables	2	4	6	20	53	29	34	34	34	34
Other payables and accruals	1	3	9	27	42	68	73	73	73	73
Short-term debt	0	0	0	0	0	0	0	0	0	0
Total current liabilities	3	7	16	48	95	97	107	107	107	107
Long-term debt	0	0	0	0	0	0	0	0	0	0
Pension liabilities	0	0	0	0	0	0	0	0	0	0
Other non-current liabilities	0	0	0	0	0	4	3	3	3	3
Total non-current liabilities	0	0	0	0	0	4	3	3	3	3
Total liabilities	3	7	16	48	95	101	110	110	110	110
Total equity and liabilities	11	86	346	760	1,045	780	474	509	362	295
<i>Key metrics</i>										
Net interest bearing debt	-7	-80	-337	-743	-1,018	-757	-440	-481	-333	-268

Source: Company (historical figures), DNB Markets (estimates)

Valuation ratios

(NOKm)	2012	2013	2014	2015	2016	2017	2018	2019e	2020e	2021e
<i>Enterprise value</i>										
Share price (NOK)			28.00	14.10	96.75	81.00	51.00	20.88	20.88	20.88
Number of shares (m)	6.37	8.84	26.55	44.52	48.78	48.78	49.11	54.37	54.37	54.37
Market capitalisation			743	628	4,720	3,952	2,505	1,135	1,135	1,135
Net interest bearing debt	-7	-80	-337	-743	-1,018	-757	-440	-481	-333	-268
Adjustments to NIBD	0	0	0	0	0	0	0	0	0	0
Net interest bearing debt adj	-7	-80	-337	-743	-1,018	-757	-440	-481	-333	-268
EV			406	-116	3,702	3,195	2,065	655	802	867
EV adj			406	-116	3,702	3,195	2,065	655	802	867
<i>Valuation</i>										
EPS	-2.11	-1.92	-3.54	-4.32	-5.05	-6.02	-6.88	-7.85	-7.32	-6.74
EPS adj	-2.11	-1.92	-3.54	-4.32	-5.05	-6.02	-6.88	-7.85	-7.32	-6.74
DPS ordinary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
DPS extraordinary	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
DPS	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
P/E			-7.9	-3.3	-19.2	-13.4	-7.4	-2.7	-2.9	-3.1
P/E adj			-7.9	-3.3	-19.2	-13.4	-7.4	-2.7	-2.9	-3.1
P/B			1.52	0.79	4.75	5.81	6.90	2.71	4.52	6.16
Average ROE	-95.5%	-39.3%	-31.1%	-33.1%	-28.3%	-36.0%	-64.6%	-106.5%	-122.4%	-168.4%
Dividend yield			0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%	0.0%
EV/SALES			924.74	-264.64	11788.65	10579.25				
EV/SALES adj			924.74	-264.64	11788.65	10579.25				
EV/EBITDA			-5.9	0.6	-17.2	-10.1	-6.1	-1.6	-2.0	-2.4
EV/EBITDA adj			-5.9	0.6	-17.2	-10.1	-6.1	-1.6	-2.0	-2.4
EV/EBIT			-5.9	0.6	-17.1	-10.1	-6.1	-1.6	-2.0	-2.4
EV/EBIT adj			-5.9	0.6	-17.1	-10.1	-6.1	-1.6	-2.0	-2.4
EV/NOPLAT			-5.9	0.6	-17.1	-10.1	-6.1	-1.6	-2.0	-2.4
EV/OpFCF (taxed)			-6.2	0.6	-17.1	-10.1	-6.1	-1.6	-2.0	-2.4

Source: Company (historical figures), DNB Markets (estimates)

Key accounting ratios

	2012	2013	2014	2015	2016	2017	2018	2019e	2020e	2021e
<i>Profitability (%)</i>										
ROA	-81.7	-35.1	-29.5	-31.2	-26.1	-32.2	-53.7	-82.6	-91.4	-111.7
<i>Return on invested capital (%)</i>										
Net PPE/revenues	186.6	109.8	357.9	642.3	1001.6	1382.1				
Working capital/revenues	498.8	-380.5	-1917.2	-7651.3	-22953.2	-25666.2				
<i>Cash flow ratios (%)</i>										
FCF/revenues	-8500.0	-5577.5	-13772.2	-39796.6	-75002.9	-97504.3				
FCF/market capitalisation			-8.1	-27.7	-5.0	-7.5	-13.4	-35.3	-35.0	-32.1
CFO/revenues	-8552.6	-5480.7	-14400.5	-39286.7	-74525.8	-96672.2				
CFO/market capitalisation			-8.5	-27.4	-5.0	-7.4	-13.4	-34.9	-34.6	-31.7
CFO/capex	16235.5	-5661.6	2292.3	-7705.7	-15621.6	-11617.6	-15503.5	-7920.0	-7856.6	-7193.4
CFO/current liabilities	-385.1	-231.8	-408.2	-360.5	-245.2	-300.2	-312.8	-370.0	-367.1	-336.1
Cash conversion ratio	93.6	100.3	95.1	100.7	100.1	100.4	100.0	98.8	100.0	99.5
Capex/revenues	-52.7	96.8	-628.2	509.8	477.1	832.1				
Capex/depreciation	-10.0	125.1	-799.3	224.1	129.1	169.5	95.9	50.0	100.0	71.4
OpFCF margin	-8699.5	-5936.9	-14919.3	-42180.5	-69012.7	-105149.7				
Total payout ratio	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0	0.0
<i>Leverage and solvency (x)</i>										
Interest cover	nm	nm	nm	nm	-7.09	nm	nm	nm	nm	nm
EBIT/interest payable	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
EBITA adj/interest payable	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm
Cash coverage	43.86	16.25	13.55	17.48	-11.44	13.64	111.07	199.00	393.83	
Net debt/EBITDA	0.51	4.45	4.93	4.08	4.73	2.40	1.30	1.21	0.85	0.75
Total debt/total capital (BV)	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
LTD / (LTD + equity (MV))			0.00	0.00	0.00	0.00	0.00	0.00	0.00	0.00
<i>Cash conversion cycle</i>										
Receivables turnover days	9927.3	7242.4	5877.1	11854.6	27173.9	23841.0	nm	nm	nm	nm
Credit period	nm	nm	nm	nm	nm	nm	nm	nm	nm	nm

Source: Company (historical figures), DNB Markets (estimates)

Important Information

Company: Nordic Nanovector
 Coverage by Analyst: Patrik Ling
 Date: 19/11/2019

This report has been prepared by DNB Markets, a division of DNB Bank ASA. DNB Bank ASA is a part of the DNB Group. This report is based on information obtained from public sources that DNB Markets believes to be reliable but which DNB Markets has not independently verified, and DNB Markets makes no guarantee, representation or warranty as to its accuracy or completeness. This report does not, and does not attempt to, contain everything material which there is to be said about the Company. Any opinions expressed herein reflect DNB Markets' judgement at the time the report was prepared and are subject to change without notice. The report is planned updated minimum every quarter.

Any use of non-DNB logos in this report is solely for the purpose of assisting in identifying the relevant issuer. DNB is not affiliated with any such issuer.

This report is for clients only, and not for publication, and has been prepared for information purposes only by DNB Markets, a division of DNB Bank ASA.

This report is the property of DNB Markets. DNB Markets retains all intellectual property rights (including, but not limited to, copyright) relating to the report. Sell-side investment firms are not allowed any commercial use (including, but not limited to, reproduction and redistribution) of the report contents, either partially or in full, without DNB Markets' explicit and prior written consent. However, buy-side investment firms may use the report when making investment decisions, and may also base investment advice given to clients on the report. Such use is dependent on the buy-side investment firm citing DNB Markets as the source.

Risk warning – generally high risk

The risk of investing in financial instruments is generally high. Past performance is not a reliable indicator of future performance, and estimates of future performance are based on assumptions that may not be realised. When investing in financial instruments, the value of the investment may increase or decrease, and the investor may lose all or part of their investment. Careful consideration of possible financial distress should be made before investing in any financial instrument.


Recommendation structure

DNB Markets recommendations are based on absolute performance:

- Buy - indicates an expected return greater than 10% within 12 months
- Hold - indicates an expected return between 0 and 10% within 12 months
- Sell - indicates an expected negative return within 12 months

Price targets are based on a combination of several valuation methods such as discounted cash flow, pricing based on earnings multiples, multiple on book value, net asset value and peer comparison. Substantial material sources for coverage of this company include historical financial figures and communication with the company, and relevant third party information. If you would like further information on the valuation, methodology or underlying assumptions used in this note, please contact the analyst (contact details on front page).

Recommendations and historical target prices below may not compile all recommendations by DNB Markets, for further information please contact DNB Markets.



Conflict of interest

DNB Markets has provided investment services and/or ancillary services to the company and received compensation for it during the past 12 months.

DNB Markets has been lead or co-lead manager related to an Investment Banking assignment for the company and received compensation for it during the past 12 months.

Readers should assume that DNB Markets may currently or may in the coming three months and beyond be providing or seeking to provide confidential investment banking services or other services to the company/companies

Share positions in the company:	Analyst*	Employees**	DNB***	Update
Number of shares	0	600	0	19/11/2019

*The analyst or any close associates. **Share positions include people involved in the production of credit and equity research, including people that could reasonably be expected to have access to it before distribution.

***Share positions as part of DNB Group. Holdings as part of DNB Markets investment services activity are not included.

Recommendation distribution and corporate clients for the last 12 months

	Buy	Hold	Sell	No_rec	Total
Number	146	62	34	10	252
% of total	58 %	25 %	13 %	4 %	
DNB Markets client	29 %	10 %	2 %	2 %	107

Legal statement

These materials constitute research as defined in section 9-27 (1) of the Norwegian Securities Trading Regulations (Norwegian: verdipapirforskriften), and are not investment advice as defined in section 2-4(1) of the Norwegian securities trading act (Norwegian verdipapirhandelloven).

The analyst hereby certifies that (i) the views expressed in this report accurately reflect that research analyst's personal views about the company and the securities that are the subject of this report, and (ii) no part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in this report. DNB Markets employees, including research analysts, may receive compensation that is generated by overall firm profitability. Confidentiality rules and internal rules restricting the exchange of information between different parts of DNB Markets/DNB Bank ASA or the DNB Group are in place to prevent employees of DNB Markets who are preparing this report from utilizing or being aware of information available in the DNB Group that may be relevant to the recipients' decisions. DNB Markets and the DNB Group have incorporated internal rules and regulations in order to avoid any potential conflicts of interest.

The Report has been prepared by DNB Markets, a division of DNB Bank ASA, a Norwegian bank organized under the laws of the Kingdom of Norway and under supervision by the Norwegian Financial Supervisory Authority, The Monetary Authority of Singapore, and on a limited basis by the Financial Conduct Authority and the Prudential Regulation Authority of the UK, and the Financial Supervisory Authority of Sweden. Details about the extent of our regulation by local authorities outside Norway are available from us on request.

It is issued subject to the General Business Terms for DNB Markets and information about the terms is available at www.dnb.no. For requests regarding the General Business Terms of the Singapore Branch of DNB Bank ASA, please contact +65 6212 6144. Information about the DNB Group can be found at www.dnb.com. DNB Markets is a member of The Norwegian Securities Dealers Association, which has issued recommendations and market standards for securities companies. The Association's Internet address where the recommendations and market standards can be found is: www.vpff.no. This report is not an offer to buy or sell any security or other financial instrument or to participate in any investment strategy. No liability whatsoever is accepted for any direct or indirect (including consequential) loss or expense arising from the use of this report. Distribution of research reports is in certain jurisdictions restricted by law. Persons in possession of this report should seek further guidance regarding such restrictions before distributing this report. Please contact DNB Markets at 08940 (+47 915 08940) for further information and inquiries regarding this report, including an overview on all recommendations from DNB Markets over the last 12 Months according to Market Abuse Regulations.

Additional information for clients in Singapore

The report has been distributed by the Singapore Branch of DNB Bank ASA. It is intended for general circulation and does not take into account the specific investment objectives, financial situation or particular needs of any particular person. You should seek advice from a financial adviser regarding the suitability of any product referred to in the report, taking into account your specific financial objectives, financial situation or particular needs before making a commitment to purchase any such product. You have received a copy of the report because you have been classified either as an accredited investor, an expert investor or as an institutional investor, as these terms have been defined under Singapore's Financial Advisers Act (Cap. 110) ("FAA") and/or the Financial Advisers Regulations ("FAR"). The Singapore Branch of DNB Bank ASA is a financial adviser exempt from licensing under the FAA but is otherwise subject to the legal requirements of the FAA and of the FAR. By virtue of your status as an accredited investor or as an expert investor, the Singapore Branch of DNB Bank ASA is, in respect of certain of its dealings with you or services rendered to you, exempt from having to comply with certain regulatory requirements of the FAA and FAR, including without limitation, sections 25, 27 and 36 of the FAA. Section 25 of the FAA requires a financial adviser to disclose material information concerning designated investment products which are recommended by the financial adviser to you as the client. Section 27 of the FAA requires a financial adviser to have a reasonable basis for making investment recommendations to you as the client. Section 36 of the FAA requires a financial adviser to include, within any circular or written communications in which he makes recommendations concerning securities, a statement of the nature of any interest which the financial adviser (and any person connected or associated with the financial adviser) might have in the securities. Please contact the Singapore branch of DNB Bank ASA at +65 6212 6144 in respect of any matters arising from, or in connection with, the report. The report is intended for and is to be circulated only to persons who are classified as an accredited investor, an expert investor or an institutional investor. If you are not an accredited investor, an expert investor or an institutional investor, please contact the Singapore Branch of DNB Bank ASA at +65 6212 6144. We, the DNB group, our associates, officers and/or employees may have interests in any products referred to in the report by acting in various roles including as distributor, holder of principal positions, adviser or lender. We, the DNB group, our associates, officers and/or employees may receive fees, brokerage or commissions for acting in those capacities. In addition, we, the DNB group, our associates, officers and/or employees may buy or sell products as principal or agent and may effect transactions which are not consistent with the information set out in the report.

In the United States

Each research analyst named on the front page of this research report, or at the beginning of any subsection hereof, hereby certifies that (i) the views expressed in this report accurately reflect that research analyst's personal views about the company and the securities that are the subject of this report; and (ii) no part of the research analyst's compensation was, is, or will be, directly or indirectly, related to the specific recommendations or views expressed by that research analyst in this report.

The research analyst(s) named on this report are foreign research analysts as defined by FINRA Rule 1050. The only affiliate contributing to this research report is DNB Bank through its DNB Markets division ("DNB Markets/DNB Bank"); the foreign research analysts employed by DNB Markets/DNB Bank are named on the first page; the foreign research analysts are not registered/qualified as research analysts with FINRA; foreign research analysts are not associated persons of DNB Markets, Inc. and therefore are not subject to the restrictions set forth in FINRA Rules 2241 and 2242 regarding restrictions on communications with a subject company, public appearances and trading securities held by a research analyst account.

This is a Third Party Research Report as defined by FINRA Rules 2241 and 2242. Any material conflict of interest that can reasonably be expected to have influenced the choice of DNB Markets/DNB Bank as a research provider or the subject company of a DNB Markets/DNB Bank research report, including the disclosures required by FINRA Rules 2241 and 2242 can be found above.

This report is being furnished solely to Major U.S. Institutional Investors within the meaning of Rule 15a-6 under the U.S. Securities Exchange Act of 1934 and to such other U.S. Institutional Investors as DNB Markets, Inc. may determine. Distribution to non-Major U.S. Institutional Investors will be made only by DNB Markets, Inc., a separately incorporated subsidiary of DNB Bank that is a U.S. broker-dealer and a member of the Financial Industry Regulatory Authority ("FINRA") and the Securities Investor Protection Corporation ("SIPC").

Any U.S. recipient of this report seeking to obtain additional information or to effect any transaction in any security discussed herein or any related instrument or investment should contact DNB Markets, Inc., 200 Park Avenue, New York, NY 10166-0396, telephone number +1 212-551-9800.

In Canada

The Report has been distributed in reliance on the International Dealer Exemption pursuant to NI 31-103 subsection 8.18(2) and subsection 8.18(4)(b). Please be advised that: 1. DNB Bank ASA (DNB Markets) and DNB Markets, Inc. are not registered as a dealer in the local jurisdiction to make the trade. We provide our services in Canada as an exempt international dealer. 2. The jurisdiction of DNB Bank ASA (DNB Markets) and DNB Markets, Inc.'s head office is Norway. 3. There may be difficulty enforcing legal rights against DNB Bank ASA (DNB Markets) and DNB Markets, Inc. because all or substantially all of their assets may be situated outside of Canada. 4. The name and address of the agent for service of process for DNB Bank ASA (DNB Markets) and DNB Markets, Inc. in the local jurisdiction is:

Alberta: Blake, Cassels & Graydon LLP, 855 - 2nd Street S.W., Suite 3500, Bankers Hall East Tower, Calgary, AB T2P 4J8. British Columbia: Blakes Vancouver Services Inc., 595 Burrard Street, P.O. Box 49314, Suite 2600, Three Bentall Centre, Vancouver, BC V7X 1L3. Manitoba: Aikins, MacAulay & Thorvaldson LLP, 30th Floor, Commodity Exchange Tower, 360 Main Street, Winnipeg, MB R3C 4G1. New Brunswick: Stewart McKelvey, Suite 1000, Brunswick House, 44 Chipman Hill, PO Box 7289, Station A, Saint John, NB E2L 2A9. Newfoundland and Labrador: Stewart McKelvey, Suite 1100, Cabot Place, 100 New Gower Street, P.O. Box 5038, St. John's, NL A1C 5V3. Nova Scotia: Stewart McKelvey, Purdy's Wharf Tower One, 1959 Upper Water Street, Suite 900, P.O. Box 997, Halifax, NS B3J 2X2. Northwest Territories: Gerald Stang, Suite 201, 5120-49 Street, Yellowknife, NT X1A 1P8. Nunavut: Field LLP, P.O. Box 1779, Building 1088C, Iqaluit, NU X0A 0H0. Ontario: Blakes Extra-Provincial Services Inc., Suite 4000, 199 Bay Street, Toronto, ON M5L 1A9. Prince Edward Island: Stewart McKelvey, 65 Grafton Street, Charlottetown, PE C1A 1K8. Québec: Services Blakes Québec Inc., 600 de Maisonneuve Boulevard Ouest, Suite 2200, Tour KPMG, Montréal, QC H3A 3J2. Saskatchewan: MacPherson, Leslie & Tyerman LLP, 1500 Continental Bank Building, 1874 Scarth Street, Regina, SK S4P 4E9. Yukon: Grant Macdonald, Macdonald & Company, Suite 200, Financial Plaza, 204 Lambert Street, Whitehorse, YK Y1A 3T2.

In Brazil

The analyst or any close associates do not hold nor do they have any direct/indirect involvement in the acquisition, sale, or intermediation of the securities discussed herein. Any financial interests, not disclosed above, that the analyst or any close associates holds in the issuer discussed in the report is limited to investment funds that do not mainly invest in the issuer or industry discussed in the report and the management of which these persons cannot influence.